WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced that BRILINTA TM (ticagrelor) tablets, a new oral antiplatelet therapy, is now available in pharmacies in the United States.
Active ingredient: Ticagrelor 90 mg; tablets. Indication: To reduce the rate of thrombotic cardiovascular (CV) events in patients with acute coronary syndrome (ACS; unstable angina or non-ST-elevation ...
Alembic Pharmaceuticals has received U.S. Food and Drug Administration final approval for an abbreviated new drug application for Ticagrelor Tablets 90 mg and tentative approval for Ticagrelor Tablets ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) today announced that BRILINTA ® (ticagrelor) tablets received Plan Preferred Tier 2 formulary access on Medco Health Solutions’ National ...
The study assessed BRILINTA ® (ticagrelor) tablets at either 60 mg twice daily or 90 mg twice daily plus once daily low-dose aspirin compared to placebo plus once daily low-dose aspirin for the ...
Mumbai, Oct. 29 -- The approved ANDA is therapeutically equivalent to the reference listed drug Brilinta Tablets, 60 mg, of AstraZeneca Pharmaceuticals LP. Ticagrelor is indicated to reduce the risk ...
AstraZeneca acknowledged today that its marketed heart disease treatment Brilinta/Brilique (ticagrelor) missed its primary endpoint in a Phase III trial intended to generate data supporting a ...
Please provide your email address to receive an email when new articles are posted on . Platelet inhibition with ticagrelor in an orodispersible tablet was similar to its standard coated form in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback